Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice

Sorafenib may improve progression-free survival (PFS) and overall survival (OS) of advanced hepatocellular carcinoma (HCC). However, the survival benefit is short lived and survivals after progressive disease (PD) have not been well characterized. This study aimed to evaluate the survival predictors...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, I-Cheng, Chen, Yi-Tzen, Chao, Yee, Huo, Teh-Ia, Li, Chung-Pin, Su, Chien-Wei, Lin, Han-Chieh, Lee, Fa-Yauh, Huang, Yi-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554055/
https://www.ncbi.nlm.nih.gov/pubmed/25860213
http://dx.doi.org/10.1097/MD.0000000000000688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554055/
https://www.ncbi.nlm.nih.gov/pubmed/25860213
http://dx.doi.org/10.1097/MD.0000000000000688

Ejemplares similares